Shohei Shirakami

Tsukuba, 3058585, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor.

Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor.

Journal: Bioorganic & medicinal chemistry

Published: July 20, 2018

Design, synthesis, and biological evaluation of novel biphenyl-4-carboxamide derivatives as orally available TRPV1 antagonists.

Design, synthesis, and biological evaluation of novel biphenyl-4-carboxamide derivatives as orally available TRPV1 antagonists.

Journal: Bioorganic & medicinal chemistry

Published: March 20, 2018

Discovery of tricyclic dipyrrolopyridine derivatives as novel JAK inhibitors.

Discovery of tricyclic dipyrrolopyridine derivatives as novel JAK inhibitors.

Journal: Bioorganic & medicinal chemistry

Published: July 07, 2017

Corrigendum to "Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3" [Bioorg. Med. Chem. 23 (2015) 4871-4883].

Corrigendum to "Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3" [Bioorg. Med. Chem. 23 (2015) 4871-4883].

Journal: Bioorganic & medicinal chemistry

Published: April 04, 2017

Corrigendum to "Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3" [Bioorg. Med. Chem. 23 (2015) 4871-4883].

Corrigendum to "Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3" [Bioorg. Med. Chem. 23 (2015) 4871-4883].

Journal: Bioorganic & medicinal chemistry

Published: August 22, 2016

AS2553627, a novel JAK inhibitor, prevents chronic rejection in rat cardiac allografts.

AS2553627, a novel JAK inhibitor, prevents chronic rejection in rat cardiac allografts.

Journal: European journal of pharmacology

Published: August 08, 2016

A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model.

A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model.

Journal: Journal of pharmacological sciences

Published: July 19, 2016

Design, synthesis, and evaluation of 4,6-diaminonicotinamide derivatives as novel and potent immunomodulators targeting JAK3.

Design, synthesis, and evaluation of 4,6-diaminonicotinamide derivatives as novel and potent immunomodulators targeting JAK3.

Journal: Bioorganic & medicinal chemistry

Published: July 01, 2016

Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3.

Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3.

Journal: Bioorganic & medicinal chemistry

Published: April 02, 2015

Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors.

Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors.

Journal: Bioorganic & medicinal chemistry

Published: March 23, 2015

Synthesis and evaluation of 1H-pyrrolo[2,3-b]pyridine derivatives as novel immunomodulators targeting Janus kinase 3.

Synthesis and evaluation of 1H-pyrrolo[2,3-b]pyridine derivatives as novel immunomodulators targeting Janus kinase 3.

Journal: Chemical & pharmaceutical bulletin

Published: March 20, 2015

Showing 1-11 of 11

Last Updated: 09/26/2026